Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial LGW Kerkmeijer, VH Groen, FJ Pos, K Haustermans, EM Monninkhof, ... Journal of Clinical Oncology 39 (7), 787-796, 2021 | 391 | 2021 |
Targeting the Hedgehog signaling pathway in cancer: beyond Smoothened A Gonnissen, S Isebaert, K Haustermans Oncotarget 6 (16), 13899, 2015 | 221 | 2015 |
Multiparametric MRI for prostate cancer localization in correlation to whole‐mount histopathology S Isebaert, L Van den Bergh, K Haustermans, S Joniau, E Lerut, ... Journal of magnetic resonance imaging 37 (6), 1392-1401, 2013 | 209 | 2013 |
Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer C Draulans, UA van der Heide, K Haustermans, FJ Pos, JV van Zyp, ... Radiotherapy and Oncology 147, 92-98, 2020 | 142 | 2020 |
Hedgehog signaling in prostate cancer and its therapeutic implication A Gonnissen, S Isebaert, K Haustermans International journal of molecular sciences 14 (7), 13979-14007, 2013 | 129 | 2013 |
Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: Toxicity in the FLAME randomized controlled trial EM Monninkhof, JWL Van Loon, M van Vulpen, LGW Kerkmeijer, FJ Pos, ... Radiotherapy and Oncology 127 (1), 74-80, 2018 | 127 | 2018 |
Final analysis of a prospective trial on functional imaging for nodal staging in patients with prostate cancer at high risk for lymph node involvement L Van den Bergh, E Lerut, K Haustermans, CM Deroose, R Oyen, ... Urologic Oncology: Seminars and Original Investigations 33 (3), 109. e23-109 …, 2015 | 105 | 2015 |
Evaluation of semi-quantitative dynamic contrast-enhanced MRI parameters for prostate cancer in correlation to whole-mount histopathology S Isebaert, F De Keyzer, K Haustermans, E Lerut, T Roskams, I Roebben, ... European journal of radiology 81 (3), e217-e222, 2012 | 85 | 2012 |
Quantitative determination of the influence of adjuvants on foliar fungicide residues B Ryckaert, P Spanoghe, G Haesaert, B Heremans, S Isebaert, ... Crop Protection 26 (10), 1589-1594, 2007 | 82 | 2007 |
Mycotoxin‐producing Fusarium Species Occurring in Winter Wheat in Belgium (Flanders) During 2002–2005 S Isebaert, S De Saeger, R Devreese, R Verhoeven, P Maene, ... Journal of Phytopathology 157 (2), 108-116, 2009 | 81 | 2009 |
A systematic assessment of radiation dose enhancement by 5-Aza-2′-deoxycytidine and histone deacetylase inhibitors in head-and-neck squamous cell carcinoma H De Schutter, M Kimpe, S Isebaert, S Nuyts International Journal of Radiation Oncology* Biology* Physics 73 (3), 904-912, 2009 | 69 | 2009 |
Patterns of failure following external beam radiotherapy with or without an additional focal boost in the randomized controlled FLAME trial for localized prostate cancer VH Groen, K Haustermans, FJ Pos, C Draulans, S Isebaert, ... European Urology 82 (3), 252-257, 2022 | 50 | 2022 |
Is there an additional value of 11C-choline PET-CT to T2-weighted MRI images in the localization of intraprostatic tumor nodules? L Van den Bergh, M Koole, S Isebaert, S Joniau, CM Deroose, R Oyen, ... International Journal of Radiation Oncology* Biology* Physics 83 (5), 1486-1492, 2012 | 50 | 2012 |
The hedgehog inhibitor GANT61 sensitizes prostate cancer cells to ionizing radiation both in vitro and in vivo A Gonnissen, S Isebaert, CM McKee, R Dok, K Haustermans, RJ Muschel Oncotarget 7 (51), 84286, 2016 | 47 | 2016 |
Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancer K Litovkin, S Joniau, E Lerut, A Laenen, O Gevaert, M Spahn, B Kneitz, ... Journal of cancer research and clinical oncology 140, 1849-1861, 2014 | 47 | 2014 |
Evaluating a decision aid for patients with localized prostate cancer in clinical practice S Isebaert, C Van Audenhove, K Haustermans, S Junius, S Joniau, ... Urologia internationalis 81 (4), 383-388, 2008 | 42 | 2008 |
DNA methylation-guided prediction of clinical failure in high-risk prostate cancer K Litovkin, A Van Eynde, S Joniau, E Lerut, A Laenen, T Gevaert, ... PLoS One 10 (6), e0130651, 2015 | 40 | 2015 |
Stereotactic body radiation therapy with optional focal lesion ablative microboost in prostate cancer: Topical review and multicenter consensus C Draulans, R De Roover, UA van der Heide, K Haustermans, F Pos, ... Radiotherapy and Oncology 140, 131-142, 2019 | 36 | 2019 |
Multicenter validation of prostate tumor localization using multiparametric MRI and prior knowledge CV Dinh, P Steenbergen, G Ghobadi, H van der Poel, SW Heijmink, ... Medical physics 44 (3), 949-961, 2017 | 33 | 2017 |
Optimal 68Ga-PSMA and 18F-PSMA PET window levelling for gross tumour volume delineation in primary prostate cancer C Draulans, R De Roover, UA van der Heide, L Kerkmeijer, RJ Smeenk, ... European Journal of Nuclear Medicine and Molecular Imaging 48, 1211-1218, 2021 | 32 | 2021 |